Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. To enhance antigen processing and cross-presentation in draining lymph nodes (DLNs), we developed an interferon (IFN)-armed RBD dimerized by an immunoglobulin fragment (I-R-F). I-R-F efficiently directs immunity against RBD to DLNs. A low dose of I-R-F induces not only high titers of long-lasting neutralizing antibodies (NAbs) but also more comprehensive T cell responses than RBD. Notably, I-R-F provides comprehensive protection in the form of a one-dose vaccine without an adjuvant. Our study shows that the pan-epitope modified human I-R-F (I-P-R-F) vaccine provides rapid and complete protection throughout the upper and lower respiratory tracts against a high-dose SARS-CoV-2 challenge in rhesus macaques. Based on these promising results, we have initiated a randomized, placebo-controlled, phase I/II trial of the human I-P-R-F vaccine (V-01) in 180 healthy adults, and the vaccine appears safe and elicits strong antiviral immune responses. Due to its potency and safety, this engineered vaccine may become a next-generation vaccine candidate in the global effort to overcome COVID-19.
【저자키워드】 Innate immunity, Biological techniques, breath, 【초록키워드】 COVID-19, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Vaccine, coronavirus, vaccination, Trial, Immunity, interferon, severe acute respiratory syndrome Coronavirus, Randomized, Adults, T cell, Receptor-binding domain, Immunoglobulin, protective immunity, RBD, immune responses, low dose, vaccine candidate, adjuvant, respiratory, placebo-controlled, lymph nodes, T cell response, rhesus macaques, Lower respiratory tract, Trigger, Safe, High-dose, acute respiratory syndrome, acute respiratory syndrome coronavirus, NAbs, effort, V-01, antigen processing, DLNs, human I-P-R-F vaccine, I-R-F, long-lasting neutralizing antibodies, upper and lower respiratory tracts, antiviral immune responses, Complete, ENhance, caused, healthy, appear, provide, overcome, long-lasting, elicit, the receptor-binding domain, induce, initiated, the vaccine, draining lymph node, dimerized, I-P-R-F, long-lasting neutralizing antibody, 【제목키워드】 SARS-CoV-2, Immunity, RBD dimer, RBD, ENhance,